Martha Morrell
CIK 1855616 · View on SEC EDGAR ↗
Insider
First SEC filing: April 20, 2021 · Latest: April 20, 2021
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 14 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
14 other filings hidden
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 5, 2024 | NPCE | S 10b5-1 | 3,446 | $15.17 | $52,276 | 77,762 Direct | -4.24% | Disposed | -0.6% (price as of 2026-08-19) |
| Feb. 2, 2024 | NPCE | S 10b5-1 | 14,143 | $15.07 | $213,135 | 81,208 Direct | -14.83% | Disposed | 0.1% (price as of 2026-08-19) |
| Feb. 1, 2024 | NPCE | S 10b5-1 | 663 | $15.04 | $9,972 | 95,351 Direct | -0.69% | Disposed | 0.3% (price as of 2026-08-19) |
| Jan. 31, 2024 | NPCE | S 10b5-1 | 1,923 | $15.08 | $28,999 | 96,014 Direct | -1.96% | Disposed | 0.0% (price as of 2026-08-19) |
| Jan. 30, 2024 | NPCE | S 10b5-1 | 11,262 | $15.10 | $170,056 | 97,937 Direct | -10.31% | Disposed | -0.1% (price as of 2026-08-19) |
| Jan. 25, 2024 | NPCE | S 10b5-1 | 1 | $15.00 | $15 | 109,199 Direct | 0.00% | Disposed | 0.5% (price as of 2026-08-19) |
| Jan. 24, 2024 | NPCE | S 10b5-1 | 827 | $15.02 | $12,422 | 109,200 Direct | -0.75% | Disposed | 0.4% (price as of 2026-08-19) |
| Dec. 27, 2023 | NPCE | S 10b5-1 | 13,300 | $10.12 | $134,596 | 110,027 Direct | -10.78% | Disposed | 49.0% (price as of 2026-08-19) |
| Dec. 26, 2023 | NPCE | S 10b5-1 | 102 | $10.00 | $1,020 | 123,327 Direct | -0.08% | Disposed | 50.8% (price as of 2026-08-19) |
| Dec. 20, 2023 | NPCE | S 10b5-1 | 2,730 | $10.14 | $27,682 | 123,429 Direct | -2.16% | Disposed | 48.7% (price as of 2026-08-19) |
| Dec. 6, 2023 | NPCE | S 10b5-1 | 11,005 | $8.16 | $89,801 | 126,159 Direct | -8.02% | Disposed | 84.8% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 27, 2024 | NPCE | Stock Option (Right to Buy) | Common Stock (24,950) | $17.11 | Feb. 26, 2034 | 24,950 | Acquired |
| Oct. 7, 2022 | NPCE | Stock Option (Right to Buy) | Common Stock (384) | $0.03 | March 8, 2023 | 384 | Disposed |
| Oct. 7, 2022 | NPCE | Stock Option (Right to Buy) | Common Stock (192) | $0.03 | Nov. 13, 2022 | 192 | Disposed |
| March 3, 2022 | NPCE | Stock Option (Right to Buy) | Common Stock (93,530) | $8.15 | March 2, 2032 | 93,530 | Acquired |
| June 4, 2021 | NPCE | Stock Option (Right to Buy) | Common Stock (16,620) | $21.67 | June 3, 2031 | 16,620 | Acquired |
| June 4, 2021 | NPCE | Stock Option (Right to Buy) | Common Stock (16,363) | $21.67 | June 3, 2031 | 16,363 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 9 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| April 20, 2021 | NPCE | Common Stock | 1,518 | Direct |
| April 20, 2021 | NPCE | Stock Option (Right to Buy)→ Common Stock (278,846) | 278,846 | Direct |
| April 20, 2021 | NPCE | Stock Option (Right to Buy)→ Common Stock (192) | 192 | Direct |
| April 20, 2021 | NPCE | Stock Option (Right to Buy)→ Common Stock (192) | 192 | Direct |
| April 20, 2021 | NPCE | Stock Option (Right to Buy)→ Common Stock (192) | 192 | Direct |
| April 20, 2021 | NPCE | Stock Option (Right to Buy)→ Common Stock (384) | 384 | Direct |
| April 20, 2021 | NPCE | Stock Option (Right to Buy)→ Common Stock (12,234) | 12,234 | Direct |
| April 20, 2021 | NPCE | Stock Option (Right to Buy)→ Common Stock (192) | 192 | Direct |
| April 20, 2021 | NPCE | Stock Option (Right to Buy)→ Common Stock (192) | 192 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
NPCE
M.D.Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $489,842 | — | $140,634 | $168,183 | $235,473 | — | — | $1,034,132 |
| 2024 | $486,702 | — | $213,875 | $287,514 | $181,460 | — | — | $1,169,551 |
| 2023 | $468,502 | — | $380,000 | — | $260,174 | — | — | $1,108,676 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.